TrialSignal transduction and targeted therapy2025

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.

Dan-Yun Ruan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.